

GLAXOSMITHKLINE PLC  
Form 6-K  
February 22, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons**

I give below details of changes in the interests of Dr M M Slaoui, a Person Discharging Managerial Responsibility, in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in the shares of his connected person following the sale of Ordinary shares at a price of \$38.26 per Ordinary share ADR on 22 February 2010 by his connected person, who is also employed by the Company, to meet her tax liabilities following the vesting of a Share Value Plan award:

| <b>No. of Shares vested</b> | <b>No. of Shares Sold</b> | <b>No. of Shares Retained</b> |
|-----------------------------|---------------------------|-------------------------------|
| 890                         | 318                       | 572                           |

The Company and Dr Slaoui's connected person were advised of these transactions on 22 February 2010.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Deputy Company Secretary

22 February 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 22 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc